잘시타빈

잘시타빈
잘시타빈 구조식 이미지
카스 번호:
7481-89-2
한글명:
잘시타빈
동의어(한글):
잘시타빈
상품명:
Zalcitabine
동의어(영문):
DDC;Hivid;dideoxycytidine;2',3'-DIDEOXYCYTIDINE;D 2C;ddCyd;I-livid;2',3'-ddC;2',3'-ddC;NSC 606170
CBNumber:
CB2369466
분자식:
C9H13N3O3
포뮬러 무게:
211.22
MOL 파일:
7481-89-2.mol
MSDS 파일:
SDS

잘시타빈 속성

녹는점
217-218 °C(lit.)
끓는 점
350.9°C (rough estimate)
알파
D25 +81° (c = 0.635 in water)
밀도
1.2605 (rough estimate)
굴절률
78 ° (C=0.5, H2O)
저장 조건
Keep in dark place,Inert atmosphere,Store in freezer, under -20°C
용해도
DMSO(약간 용해됨, 가열), 메탄올(약간 용해됨), 물(약간 용해됨, 초음파 처리)
물리적 상태
가루
산도 계수 (pKa)
14.44±0.10(Predicted)
색상
무색의
수용성
19&C에서 5~10g/100mL
Merck
14,10109
BRN
654956
안정성
안정적인. 타기 쉬운. 강한 산화제와 호환되지 않습니다.
InChIKey
WREGKURFCTUGRC-POYBYMJQSA-N
CAS 데이터베이스
7481-89-2(CAS DataBase Reference)
IARC
2B (Vol. 76) 2000
EPA
Cytidine, 2',3'-dideoxy- (7481-89-2)
안전
  • 위험 및 안전 성명
  • 위험 및 사전주의 사항 (GHS)
위험품 표기 Xn,C
위험 카페고리 넘버 40-36/37-34
안전지침서 22-36-45-36/37/39-27-26
WGK 독일 3
RTECS 번호 HA3870000
F 고인화성물질 10-23
HS 번호 2934990002
유해 물질 데이터 7481-89-2(Hazardous Substances Data)
그림문자(GHS): GHS hazard pictograms
신호 어: Warning
유해·위험 문구:
암호 유해·위험 문구 위험 등급 범주 신호 어 그림 문자 P- 코드
H351 암을 일으킬 것으로 의심됨 (노출되어도 암을 일으키지 않는다는 결정적인 증거가 있는 노출경로가 있다면 노출경로 기재) 발암성 물질 구분 2 경고 P201, P202, P281, P308+P313, P405,P501
예방조치문구:
P281 요구되는 개인 보호구를 착용하시오
NFPA 704
1
2 0

잘시타빈 MSDS


DDC

잘시타빈 C화학적 특성, 용도, 생산

개요

Zalcitabine is an orally active dideoxynucleoside andog for combination use with zidovudine in advanced HIV infection and also as monotherapy for AIDS patients who cannot tolerate or have not responded to zidovudine. It has a similar mechanism of action (inhibition of reverse transcriptase) to didanosine. Like didanosine, its side effect profile includes peripheral neuropathy. Unlike zidovudine, zalcitabine does not cause bone marrow suppression.

화학적 성질

White to Off-White Cyrstalline Powder

Indications

Zalcitabine (ddC, Hivid) is a cytidine analogue active against HIV-1, HIV-2, and hepatitis B virus. It is used for the treatment of HIV infection in adults and asymptomatic children as part of a multidrug regimen. It may be less effective than the other nucleoside inhibitors and is used less frequently.

정의

ChEBI: A pyrimidine 2',3'-dideoxyribonucleoside compound having cytosine as the nucleobase.

일반 설명

Zalcitabine, 2',3'-dideoxycytidine or ddCyd, is an analog ofcytosine that demonstrates activity against HIV-1 and HIV-2,including strains resistant to AZT. The potency (in peripheralblood mononuclear cells) is similar to that of AZT, but thedrug is more active in populations of monocytes andmacrophages as well as in resting cells.
The oral bioavailability of zalcitabine is over 80% in adultsand less in children.The major dose-limiting side effect isperipheral neuropathy, characterized by pain, paresthesias,and hypesthesia, beginning in the distal lower extremities.These side effects are typically evident after several months oftherapy with zalcitabine. A potentially fatal pancreatitis is anothertoxic effect of treatment with ddC. The drug has beenapproved for the treatment of HIV infection in adults with advanceddisease who are intolerant to AZT or who have diseaseprogression while receiving AZT. ddC is combined with AZTfor the treatment of advanced HIV infection.

공기와 물의 반응

Water soluble.

반응 프로필

Zalcitabine may be sensitive to prolonged exposure to light.

화재위험

Flash point data for Zalcitabine are not available; however, Zalcitabine is probably combustible.

Pharmacology

Peripheral neuropathy occurs in up to 50% of patients taking zalcitabine. Stomatitis, esophageal ulceration, hepatotoxicity, rash, and pancreatitis may occur. Zalcitabine should be used with caution in individuals with a history of pancreatitis, liver disease, or alcohol abuse. Dosage adjustment is necessary for individuals with renal impairment. Zalcitabine should not be used in combination with didanosine, lamivudine, or stavudine.

Pharmacokinetics

Zalcitabine (ddC) is a useful alternate drug to ZDV and is given in combination with ZDV when CD4 cell counts fall to less than 300 cells/mm3 . Monotherapy with ddC is more active than ZDV. Its oral bioavailability is 87%, and its plasma half-life is approximately 1 hour. In low doses (0.005 mg/kg every 4 hours), ddC produces sustained decrease in p24 antigen level and increase in CD4 cell counts. The CSF fluid/plasma ratio of ddC is 0.2. Following oral administration, bioavailability of ddC is less than 80%, which is further reduced when taken with food. The mean maximum plasma concentration of the drug also is reduced from 25.2 to 15.5 ng/mL when the drug was taken with food.

부작용

It has side effects, such as stomatitis, rash, fever, malaise, arthritis, and arthralgia.

신진 대사

Dideoxyuridine is the major metabolite in urine and feces. The drug penetrates the blood-brain barrier. The major toxicity of ddC is peripheral neuropathy, in which case it should be discontinued. In some cases, pancreatitis occurs when given alone or in combination with ZDV."

잘시타빈 준비 용품 및 원자재

원자재

준비 용품


잘시타빈 공급 업체

글로벌( 352)공급 업체
공급자 전화 이메일 국가 제품 수 이점
Hebei Mojin Biotechnology Co., Ltd
+8613288715578
sales@hbmojin.com China 12470 58
Hebei Yanxi Chemical Co., Ltd.
+8617531190177
peter@yan-xi.com China 6011 58
hebei hongtan Biotechnology Co., Ltd
+86-86-1913198-3935 +8617331935328
sales03@chemcn.cn China 971 58
career henan chemical co
+86-0371-86658258
sales@coreychem.com China 29914 58
Jinan Carbotang Biotech Co.,Ltd.
+8615866703830
figo.gao@foxmail.com China 7154 58
Hubei Jusheng Technology Co.,Ltd.
18871490254
linda@hubeijusheng.com CHINA 28180 58
Nanjing Baifuli Technology Co., Ltd.
+86-15335185688
sales@unisyn.cn CHINA 332 58
Hubei xin bonus chemical co. LTD
86-13657291602
linda@hubeijusheng.com CHINA 22968 58
BOC Sciences
+1-631-485-4226
inquiry@bocsci.com United States 19553 58
Chongqing Chemdad Co., Ltd
+86-023-6139-8061 +86-86-13650506873
sales@chemdad.com China 39916 58

잘시타빈 관련 검색:

Copyright 2019 © ChemicalBook. All rights reserved